Business, energy, technology, markets and global industry news from Business News Today

non-small cell lung cancer

PharmaDeviceNews non-small cell lung cancer
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Representative image of an oncology consultation involving lung scan review, reflecting how Xcovery Holdings’ Ensacove launch and EVERSANA’s commercialization support could influence patient access in ALK-positive non-small cell lung cancer care.
Pharma & Biotech

Can EVERSANA help Xcovery turn Ensacove into a serious ALK-positive lung cancer contender?

ALK lung cancer has strong therapies already. Xcovery’s Ensacove now faces the harder test of access, adoption, and differentiation.

Read More
Pharma & Biotech

Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.

CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.

Read More
Pharma & Biotech

From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026

Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.

Read More
Pharma & Biotech

STK-012 shows promise in resistant lung cancer biology, but can Synthekine deliver in Phase 2?

Synthekine’s STK-012 showed encouraging AACR 2026 data in resistant NSCLC. Read what the results could mean for frontline lung cancer treatment.

Read More
Pharma & Biotech

Why Lantern Pharma’s LP-300 data in EGFR L858R NSCLC could reshape the post-osimertinib debate

Lantern Pharma’s LP-300 showed an early EGFR L858R lung cancer signal. Read what the FDA meeting and trial redesign could change next.

Read More
Pharma & Biotech

Salubris Biotherapeutics expands JK06 data at AACR 2026 with encouraging responses in difficult solid tumors

Salubris Biotherapeutics’ JK06 showed early AACR 2026 activity in NSCLC and breast cancer. Read what it could mean for the 5T4 ADC race.

Read More
Representative image of lung cancer immunotherapy research as Innate Pharma advances IPH5201 in the MATISSE Phase 2 trial for resectable non-small cell lung cancer at AACR 2026.
Pharma & Biotech

Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis

Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.

Read More
Pharma & Biotech

Why Tubulis gives Gilead more than just another antibody-drug conjugate asset

Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.

Read More
Pharma & Biotech

Can Synthekine’s STK-012 overcome immunotherapy resistance in first-line NSCLC patients?

Can STK-012 overcome immunotherapy resistance in lung cancer? Explore AACR 2026 data and what it means for IL-2 precision therapies.

Read More